Literature DB >> 9058592

Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.

C L Cioffi1, M Garay, J F Johnston, K McGraw, R T Boggs, D Hreniuk, B P Monia.   

Abstract

Raf kinases, cytoplasmic serine/threonine protein kinases, have been proposed as important participants in mitogen-induced signal transduction. However, the precise role that Raf kinase isozymes play in cellular responses such as proliferation has not been resolved. The present study investigates the ability of antisense phosphorothioate oligodeoxynucleotides (ODNs), targeted against rat C-Raf and A-Raf kinases, to reduce gene expression and proliferation of cultured rat A10 smooth muscle cells (SMCs). Exposure of A10 cells to ISIS 11061, an active C-Raf antisense ODN, resulted in a potent, dose-dependent inhibition (IC50 = 55 nM) of C-Raf mRNA and protein expression. This inhibition was completely dependent on ODN sequence because the incorporation of increasing numbers of mismatches (up to six) into the sequence resulted in sequential loss of potency. Similarly, a dose-dependent reduction (IC50 = 125 nM) in A-Raf gene expression was observed after treatment of cells with the active A-Raf ODN, ISIS 9069, whereas two scrambled controls were without effect. These results demonstrate that ISIS 11061 and ISIS 9069 reduced gene expression in a sequence-specific and isozyme-specific manner. Moreover, administration of ISIS 11061 and ISIS 9069 to rat SMCs resulted in a significant and potent diminution of serum-induced proliferation with corresponding IC50 values of 216 and 273 nM, respectively. Taken together, these results indicate that A-Raf and C-Raf kinases play an important role in regulating vascular SMC proliferation and that antisense-mediated inhibition of Raf kinase activity may serve as a therapeutic modality in the treatment of vascular proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058592

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.

Authors:  Thazha P Prakash; Joseph F Johnston; Mark J Graham; Thomas P Condon; Muthiah Manoharan
Journal:  Nucleic Acids Res       Date:  2004-02-03       Impact factor: 16.971

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Mapping of accessible sites for oligonucleotide hybridization on hepatitis delta virus ribozymes.

Authors:  J Wrzesinski; M Legiewicz; J Ciesiołka
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

Review 5.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

6.  IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Authors:  Jason D Ferrone; Gourab Bhattacharjee; Alexey S Revenko; Thomas A Zanardi; Marshelle S Warren; Frederick J Derosier; Nicholas J Viney; Nguyen C Pham; Gwendolyn E Kaeser; Brenda F Baker; Eugene Schneider; Steven G Hughes; Brett P Monia; A Robert MacLeod
Journal:  Nucleic Acid Ther       Date:  2019-02-28       Impact factor: 5.486

7.  Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency.

Authors:  Chien-Ju Chen; Martina Sgritta; Jacqunae Mays; Hongyi Zhou; Rocco Lucero; Jin Park; I-Ching Wang; Jun Hyoung Park; Benny Abraham Kaipparettu; Loredana Stoica; Paymaan Jafar-Nejad; Frank Rigo; Jeannie Chin; Jeffrey L Noebels; Mauro Costa-Mattioli
Journal:  Nat Med       Date:  2019-10-21       Impact factor: 53.440

8.  Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver.

Authors:  Tatsuya Yamada; Daisuke Murata; David E Kleiner; Robert Anders; Avi Z Rosenberg; Jeffrey Kaplan; James P Hamilton; Mariam Aghajan; Moshe Levi; Nae-Yuh Wang; Ted M Dawson; Toru Yanagawa; Andrew F Powers; Miho Iijima; Hiromi Sesaki
Journal:  iScience       Date:  2022-02-26

9.  Silencing ARAF Suppresses the Malignant Phenotypes of Gallbladder Cancer Cells.

Authors:  Weiguo Lin; Chenhao Tong; Weiguang Zhang; Wenda Cen; Yali Wang; Jiandong Li; Zhiyang Zhu; Jianhua Yu; Baochun Lu
Journal:  Biomed Res Int       Date:  2020-08-18       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.